Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 4 1

Status

Recruiting 4Active not recruiting 3Completed 2Not yet recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Burkitt Lymphoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

pembrolizumab 562Specimen Handling 490Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 406Radiotherapy 353Gemcitabine 314Bevacizumab 313Paclitaxel 298Biopsy 290Drug Therapy 283Blood Specimen Collection 248Capecitabine 245Oxaliplatin 241fludarabine 240Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 205Dexamethasone 187Radiosurgery 182Rituximab 159Standard of Care 158Pemetrexed 156Surgical Procedures, Operative 148durvalumab 145atezolizumab 145Leucovorin 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Medrol Veriderm × Clear all
NCT06317662 2026-06-03

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

National Cancer Institute (NCI)

Phase 2 Recruiting
153 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT02464696 2026-03-05

Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

M.D. Anderson Cancer Center

Phase NA Recruiting
256 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT07101445 2026-02-10

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Emory University

Phase 4 Recruiting
94 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡